Tryptamine Therapeutics Welcomes New CFO
Company Announcements

Tryptamine Therapeutics Welcomes New CFO

Tryptamine Therapeutics (AU:TYP) has released an update.

Tryptamine Therapeutics Limited has announced the appointment of Hamish George as the new Chief Financial Officer, bringing his decade-long expertise in finance and commercial experience to the clinical-stage biotech company. George’s previous roles include Director at Bio101 Financial Advisory and CFO for multiple organizations, poised to aid the company’s development of novel psilocybin-based therapies. The company expressed gratitude to former CFO Jim O’Neill for his contributions and smooth transition of responsibilities to George.

For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App